Mirit I. Aladjem
YOU?
Author Swipe
View article: CellMiner cross-database (CellMinerCDB) version 2.2 for explorations of patient-derived cancer cell line pharmacogenomics
CellMiner cross-database (CellMinerCDB) version 2.2 for explorations of patient-derived cancer cell line pharmacogenomics Open
CellMiner Cross-Database (CellMinerCDB) (https://discover.nci.nih.gov/cellminercdb/) is an established interactive application providing direct access and enabling exploration of cancer cell line pharmacogenomics without extensive programm…
View article: Tumor-targeted top1 inhibitor delivery with optimized parp inhibition in advanced solid tumors: a phase i trial of gapped scheduling
Tumor-targeted top1 inhibitor delivery with optimized parp inhibition in advanced solid tumors: a phase i trial of gapped scheduling Open
Despite mechanistic rationale for combining PARP inhibitors with topoisomerase I inhibitors, clinical use has been hindered by dose-limiting toxicities. We hypothesized that integrating tumor-targeted topoisomerase I inhibitor delivery wit…
View article: SCLC-TumorMiner: A Directly Accessible Genomics Resource for Precision Oncology – Big Data for Small Cells
SCLC-TumorMiner: A Directly Accessible Genomics Resource for Precision Oncology – Big Data for Small Cells Open
SUMMARY RNAseq and DNAseq are fast, cost-effective and quantitative methods to dissect cancer cells. However, for each sample, they generate thousands of data points, and comparing patient samples multiplies the complexity. To handle these…
View article: NOTCH1 reverses immune suppression in small cell lung cancer through reactivation of STING
NOTCH1 reverses immune suppression in small cell lung cancer through reactivation of STING Open
Downregulation of antigen presentation and lack of immune infiltration are defining features of small cell lung cancer (SCLC), limiting response to immune checkpoint blockade (ICB). While a high-MHC class I, immune-inflamed subset benefits…
View article: Bimodal Genomic Approach Predicting Semaphorin 7A (SEMA7A) as Prognostic Biomarker in Adrenocortical Carcinoma
Bimodal Genomic Approach Predicting Semaphorin 7A (SEMA7A) as Prognostic Biomarker in Adrenocortical Carcinoma Open
Background: Adrenocortical carcinoma (ACC) is a rare and aggressive endocrine malignancy with a high mortality and poor prognosis. To elucidate the genetic underpinnings of ACCs, we have analyzed the transcriptome profiles of ACC tumor sam…
View article: Selective interactions at pre-replication complexes categorize baseline and dormant origins
Selective interactions at pre-replication complexes categorize baseline and dormant origins Open
DNA synthesis in metazoans initiates within a select group of replication origins (baseline origins), whereas other (dormant) origins do not initiate replication despite recruiting apparently indistinguishable pre-replication complexes. Do…
View article: Bimodal genomic approach predicting Semaphorin 7A (SEMA7A) as prognostic biomarker in adrenocortical carcinoma
Bimodal genomic approach predicting Semaphorin 7A (SEMA7A) as prognostic biomarker in adrenocortical carcinoma Open
Adrenocortical carcinoma (ACC) is a rare and aggressive endocrine malignancy with high mortality and poor prognosis. To elucidate the genetic underpinnings of ACCs, we have analyzed the transcriptome data of 112 ACC tumor samples from pati…
View article: D-2-hydroxyglutarate impairs DNA repair through epigenetic reprogramming
D-2-hydroxyglutarate impairs DNA repair through epigenetic reprogramming Open
Cancer-associated mutations in IDH are associated with multiple types of human malignancies, which exhibit distinctive metabolic reprogramming, production of oncometabolite D-2-HG, and shifted epigenetic landscape. IDH mutated malignancies…
View article: A dual role of Cohesin in DNA DSB repair
A dual role of Cohesin in DNA DSB repair Open
Cells undergo tens of thousands of DNA-damaging events each day. Defects in repairing double-stranded breaks (DSBs) can lead to genomic instability, contributing to cancer, genetic disorders, immunological diseases, and developmental defec…
View article: CCRG-01. MYT1 BLOCKADE AS A NOVEL GLIOMA THERAPEUTICS THROUGH ABROGATIING OF THE G2/M CELL CYCLE CHECKPOINT
CCRG-01. MYT1 BLOCKADE AS A NOVEL GLIOMA THERAPEUTICS THROUGH ABROGATIING OF THE G2/M CELL CYCLE CHECKPOINT Open
BACKGROUND The cell cycle is tightly regulated by checkpoints, which play a vital role in controlling its progression and timing. Cancer cells exploit the G2/M checkpoint, which serves as a resistance mechanism against genotoxic anticancer…
View article: Metastatic organotropism in small cell lung cancer
Metastatic organotropism in small cell lung cancer Open
Metastasis is the leading cause of cancer-related deaths, yet its regulatory mechanisms are not fully understood. Small-cell lung cancer (SCLC) is the most metastatic form of lung cancer, with most patients presenting with widespread disea…
View article: Data from Targeting Replication Stress and Chemotherapy Resistance with a Combination of Sacituzumab Govitecan and Berzosertib: A Phase I Clinical Trial
Data from Targeting Replication Stress and Chemotherapy Resistance with a Combination of Sacituzumab Govitecan and Berzosertib: A Phase I Clinical Trial Open
Purpose: Despite promising preclinical studies, toxicities have precluded combinations of chemotherapy and DNA damage response (DDR) inhibitors. We hypothesized that tumor-targeted chemotherapy delivery might enable clinical translation of…
View article: Supplementary Figure S2 from Targeting Replication Stress and Chemotherapy Resistance with a Combination of Sacituzumab Govitecan and Berzosertib: A Phase I Clinical Trial
Supplementary Figure S2 from Targeting Replication Stress and Chemotherapy Resistance with a Combination of Sacituzumab Govitecan and Berzosertib: A Phase I Clinical Trial Open
Pharmacokinetic assessment
View article: Supplementary Figure S3 from Schlafen 11 (SLFN11) kills cancer cells undergoing unscheduled re-replication
Supplementary Figure S3 from Schlafen 11 (SLFN11) kills cancer cells undergoing unscheduled re-replication Open
Figure S3
View article: Supplementary Figure S1 from Schlafen 11 (SLFN11) kills cancer cells undergoing unscheduled re-replication
Supplementary Figure S1 from Schlafen 11 (SLFN11) kills cancer cells undergoing unscheduled re-replication Open
Figure S1
View article: Data from Schlafen 11 (SLFN11) kills cancer cells undergoing unscheduled re-replication
Data from Schlafen 11 (SLFN11) kills cancer cells undergoing unscheduled re-replication Open
SLFN11 is an increasingly prominent predictive biomarker and a molecular sensor for a wide range of clinical drugs: topoisomerases, PARP and replication inhibitors, and platinum derivatives. To expand the spectrum of drugs and pathways tar…
View article: Supplementary Table S3 from Schlafen 11 (SLFN11) kills cancer cells undergoing unscheduled re-replication
Supplementary Table S3 from Schlafen 11 (SLFN11) kills cancer cells undergoing unscheduled re-replication Open
Data for Figure 4B
View article: Supplementary Figure S1 from Targeting Replication Stress and Chemotherapy Resistance with a Combination of Sacituzumab Govitecan and Berzosertib: A Phase I Clinical Trial
Supplementary Figure S1 from Targeting Replication Stress and Chemotherapy Resistance with a Combination of Sacituzumab Govitecan and Berzosertib: A Phase I Clinical Trial Open
Berzosertib pharmacodynamic assessment
View article: Supplementary Table S3 from Schlafen 11 (SLFN11) kills cancer cells undergoing unscheduled re-replication
Supplementary Table S3 from Schlafen 11 (SLFN11) kills cancer cells undergoing unscheduled re-replication Open
Data for Figure 4B
View article: Supplementary Table S2 from Targeting Replication Stress and Chemotherapy Resistance with a Combination of Sacituzumab Govitecan and Berzosertib: A Phase I Clinical Trial
Supplementary Table S2 from Targeting Replication Stress and Chemotherapy Resistance with a Combination of Sacituzumab Govitecan and Berzosertib: A Phase I Clinical Trial Open
Study Representativeness
View article: Supplementary Figure S4 from Targeting Replication Stress and Chemotherapy Resistance with a Combination of Sacituzumab Govitecan and Berzosertib: A Phase I Clinical Trial
Supplementary Figure S4 from Targeting Replication Stress and Chemotherapy Resistance with a Combination of Sacituzumab Govitecan and Berzosertib: A Phase I Clinical Trial Open
Comparison of treatment-related adverse events with the combination of berzosertib and topotecan
View article: Supplementary Table S1 from Schlafen 11 (SLFN11) kills cancer cells undergoing unscheduled re-replication
Supplementary Table S1 from Schlafen 11 (SLFN11) kills cancer cells undergoing unscheduled re-replication Open
Results of HTS in CCRF-CEM parent and SLFN11-KO cells
View article: Supplementary Figure S4 from Targeting Replication Stress and Chemotherapy Resistance with a Combination of Sacituzumab Govitecan and Berzosertib: A Phase I Clinical Trial
Supplementary Figure S4 from Targeting Replication Stress and Chemotherapy Resistance with a Combination of Sacituzumab Govitecan and Berzosertib: A Phase I Clinical Trial Open
Comparison of treatment-related adverse events with the combination of berzosertib and topotecan
View article: Supplementary Table S2 from Schlafen 11 (SLFN11) kills cancer cells undergoing unscheduled re-replication
Supplementary Table S2 from Schlafen 11 (SLFN11) kills cancer cells undergoing unscheduled re-replication Open
Results of HTS in K562+Vector and K562+WT SLFN11 cells
View article: Supplementary Table S1 from Schlafen 11 (SLFN11) kills cancer cells undergoing unscheduled re-replication
Supplementary Table S1 from Schlafen 11 (SLFN11) kills cancer cells undergoing unscheduled re-replication Open
Results of HTS in CCRF-CEM parent and SLFN11-KO cells
View article: Supplementary Table S2 from Targeting Replication Stress and Chemotherapy Resistance with a Combination of Sacituzumab Govitecan and Berzosertib: A Phase I Clinical Trial
Supplementary Table S2 from Targeting Replication Stress and Chemotherapy Resistance with a Combination of Sacituzumab Govitecan and Berzosertib: A Phase I Clinical Trial Open
Study Representativeness
View article: Supplementary Figure S2 from Schlafen 11 (SLFN11) kills cancer cells undergoing unscheduled re-replication
Supplementary Figure S2 from Schlafen 11 (SLFN11) kills cancer cells undergoing unscheduled re-replication Open
Figure S2